Greenleaf Trust Sells 393 Shares of Illumina, Inc. (ILMN)

Greenleaf Trust trimmed its holdings in Illumina, Inc. (NASDAQ:ILMN) by 5.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,749 shares of the life sciences company’s stock after selling 393 shares during the period. Greenleaf Trust’s holdings in Illumina were worth $2,477,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in ILMN. Jennison Associates LLC lifted its position in shares of Illumina by 4.5% during the second quarter. Jennison Associates LLC now owns 4,297,581 shares of the life sciences company’s stock valued at $1,200,271,000 after purchasing an additional 185,745 shares in the last quarter. Fred Alger Management Inc. lifted its position in shares of Illumina by 21.4% during the second quarter. Fred Alger Management Inc. now owns 778,450 shares of the life sciences company’s stock valued at $217,413,000 after purchasing an additional 137,302 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its position in shares of Illumina by 5.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 604,615 shares of the life sciences company’s stock valued at $168,863,000 after purchasing an additional 31,985 shares in the last quarter. Millennium Management LLC lifted its position in shares of Illumina by 219.8% during the second quarter. Millennium Management LLC now owns 548,957 shares of the life sciences company’s stock valued at $153,318,000 after purchasing an additional 377,283 shares in the last quarter. Finally, Federated Investors Inc. PA lifted its position in shares of Illumina by 4.1% during the second quarter. Federated Investors Inc. PA now owns 512,611 shares of the life sciences company’s stock valued at $143,167,000 after purchasing an additional 20,324 shares in the last quarter. 89.87% of the stock is currently owned by hedge funds and other institutional investors.

ILMN has been the topic of a number of recent analyst reports. ValuEngine lowered shares of Illumina from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 11th. Canaccord Genuity reissued a “buy” rating and set a $340.00 price target (up from $330.00) on shares of Illumina in a research report on Friday, July 27th. Barclays raised their price target on shares of Illumina from $350.00 to $370.00 and gave the company an “overweight” rating in a research report on Wednesday, October 24th. Deutsche Bank raised their price target on shares of Illumina from $280.00 to $330.00 and gave the company a “buy” rating in a research report on Tuesday, July 31st. Finally, BidaskClub raised shares of Illumina from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 1st. Six investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Illumina presently has a consensus rating of “Buy” and an average target price of $330.94.



NASDAQ ILMN opened at $292.25 on Tuesday. Illumina, Inc. has a 52-week low of $203.03 and a 52-week high of $372.61. The company has a debt-to-equity ratio of 0.24, a current ratio of 2.46 and a quick ratio of 2.24. The stock has a market cap of $43.38 billion, a P/E ratio of 73.06, a P/E/G ratio of 2.19 and a beta of 0.97.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, October 23rd. The life sciences company reported $1.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.26 by $0.26. Illumina had a net margin of 21.09% and a return on equity of 27.10%. The business had revenue of $853.00 million during the quarter, compared to the consensus estimate of $825.65 million. During the same quarter last year, the company posted $1.11 earnings per share. The firm’s quarterly revenue was up 19.5% compared to the same quarter last year. On average, equities research analysts anticipate that Illumina, Inc. will post 5.75 EPS for the current year.

In other news, Director Jay T. Flatley sold 3,300 shares of Illumina stock in a transaction dated Wednesday, October 24th. The shares were sold at an average price of $310.58, for a total value of $1,024,914.00. Following the completion of the transaction, the director now owns 382,304 shares in the company, valued at $118,735,976.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Mostafa Ronaghi sold 10,000 shares of Illumina stock in a transaction dated Friday, August 10th. The stock was sold at an average price of $331.39, for a total transaction of $3,313,900.00. The disclosure for this sale can be found here. Insiders have sold 55,283 shares of company stock valued at $18,571,402 in the last 90 days. 0.54% of the stock is currently owned by corporate insiders.

About Illumina

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Featured Story: What does RSI mean?

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply